Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: REPL stock price vs AMAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMAT's multiple
Needs Revenue / share, AMAT P/S.
Implied fair value · at REPL's multiple
Needs REPL P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: REPL FY 2026 (ended Mar 31, 2026) · AMAT FY 2025 (ended Oct 26, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
REPLIMUNE GROUP, INC. · implied price per share
Cash flow and years must be positive.
APPLIED MATERIALS INC /DE · implied price per share
Bear
$93.60
Base
$110.12
Bull
$126.64
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.50x
0.32x
Net debt / EBITDA
Leverage against operating earnings
0.60x
-0.20x
Cash and equivalents
Liquid reserves on the balance sheet
$268.89M
$8.57B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REPL vs AMGN
INCYTE CORP
REPL vs INCY
Blueprint Medicines Corp
REPL vs BPMC
Adaptive Biotechnologies Corp
REPL vs ADPT
LAM RESEARCH CORP
REPL vs LRCX
ASML HOLDING NV
REPL vs ASML
TERADYNE, INC
REPL vs TER
MKS INSTRUMENTS INC
REPL vs MKSI
KLA CORP
REPL vs KLAC
SKYWORKS SOLUTIONS, INC.
REPL vs SWKS
$83.31M
$6.56B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe REPL can materially improve profitability and quality scores from today’s weak baseline, then a cautious hold or selective buy could make sense because the stock is trading within its historical range and the downside gap is not obvious from the limited data provided.
REPL’s current price of $11.58 sits inside its historical band of $10.42 to $12.74, suggesting no obvious valuation dislocation from the data provided. Unlike AMAT, which has clearly defined revenue and earnings power, REPL lacks enough reported operating metrics here to support a clean relative valuation gap.
Supporting Metrics
